Imatinib targeted therapy for a patient with chronic eosinophilic leukemia;Celowana terapia imatinibem u chorego z przewlekła białaczka eozynofilowa

Wspolczesna Onkologia

Volumn 9, Issue 1, 2005, Pages 7-10

  Prejzner, Witold ^a   Szatkowski, Damian ^a   Wasag, Bartosz ^a   Limon, Janusz ^a   Hellmann, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chronic eosinophilic leukemia; Gene FIP1L1 PDGFRA; Hypereosinophilic syndrome; Imatinib

Indexed keywords

BUSULFAN; HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC LEUKEMIA; CLONAL VARIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG TARGETING; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; GENE FUSION; GENE MUTATION; HEART FAILURE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA REMISSION; LUNG INSUFFICIENCY; MAINTENANCE THERAPY; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MOLECULAR GENETICS; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; WORLD HEALTH ORGANIZATION;

EID: 16344392969     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Chusid MJ, Dale D, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
3. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001; 3: 9.
4. Hellmann A, Prejzner W. Eozynofilia - szlaki poszukiwania przyczyny. Acta Haematol Pol 2002; 33 supl 1: 34-42.
5. Parillo JE, Fauci A, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978; 89: 167-72.
6. Hałaburda K, Wiśniewski M, Zaucha JM i wsp. Allogeniczne przeszczepianie szpiku kostnego u chorego z zespołem hypereozynofilowym. Acta Heamtol Pol 2003; 34: 253-9.
7. Hellmann A, Prejzner W. STI571 - nowy lek w leczeniu przewlekłej białaczki szpikowej. Acta Haematol Pol 2001; 32: 5-13.
8. Gleich GJ, Leiferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-8.
9. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101 (9): 3391-7.
10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
11. Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100: 7830-5.
12. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18: 734-42.
13. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101 (12): 4714-6.
14. Martinelli G, Malagola M, Ottaviani E, et al. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica 2004; 89: 236-7.
15. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 2004; 28 Suppl 1: S47-52.